Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Waxsol is an over-the-counter otic preparation containing 0.5% w/v docusate sodium, a surfactant that acts as a cerumenolytic to soften and disperse impacted ear wax, facilitating its natural removal from the external auditory canal. By lowering surface tension and penetrating the cerumen mass, docusate sodium breaks up and emulsifies ear wax, improving clearance and relieving conductive hearing loss and discomfort associated with impaction. Waxsol is indicated as an aid in the removal of ear wax in adults, the elderly and children (with age restrictions varying by jurisdiction), and is typically used once nightly for up to two consecutive nights before reassessment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Waxsol.